PALV-04, NCT04893486: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome |
|
|
| Completed | 2 | 73 | Europe, US | PTX-022, Vehicle comparator | Palvella Therapeutics, Inc. | BCCs in Gorlin Syndrome Patients | 03/23 | 03/23 | | |
